Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2015, 24(3):160-165

What is a structural myocardial remodeling?

Murín J1, Pernický M1, Klabník A2, Kyčina P3, Bulas J1, Kiňová S1
1 I. interná klinika LFUK a UN Bratislava
2 Kardiologická ambulancia Hornooravská NsP, Trstená
3 Jednotka intenzívnej starostlivosti Interného oddelenia, Liptovská nemocnica, Liptovský Mikuláš, Slovenská republika

Structural myocardial remodeling is an important concept in understanding chronic heart failure disease. Its recognition leads to important treatments of heart failure, mainly to blocking of the activation of neurohormonal systems in these patients. The authors try to summarize known experience about structural remodeling, focusing mainly on cardiovascular inflammation, on collagen matrix alteration and on cardiomyocyte damage during the progression of heart failure. They also try to look for possible treatments. Fig. 2, Lit. 54, Online full text (Free, PDF) www. cardiology.sk

Keywords: heart failure; structural myocardial remodeling; cardiovascular inflammation; collagen matrix alteration; possible treatments in myocardial remodeling

Published: March 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Murín J, Pernický M, Klabník A, Kyčina P, Bulas J, Kiňová S. What is a structural myocardial remodeling? Cardiology Letters. 2015;24(3):160-165.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cohn JN, Ferrari R, Sharpe N on behalf of an International Forum on Cardiac Remodeling. Cardiac remodeling: concepts and clinical implications: a consensus paper from an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000;35:569582. Go to original source...
    2. Kehat I, Molkentin JD. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 2010;122:2727-2735. Go to original source...
    3. Asakura M, Kitakaze M. Global gene expression profiling in the failing myocardium. Circ J 2009;73:1568-1576. Go to original source...
    4. Paulus WJ. Cytokines and heart failure. Heart Fail Monit 2000;1:5056. Go to original source...
    5. Satoh M, Minami Y, Takahashi Y, et al. Immune modulation: role of the inflammatory cytokine cascade in the failing human heart. Curr Heart Fail Rep 2008;5:69-74. Go to original source...
    6. Dobaczewski M, Gonzalez-Quesada C, Frangogiannis NG. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J Mol Cell Cardiol 2010;48:504-511. Go to original source...
    7. Frangogiannis FG. The immune system and cardiac repair. Pharmacol Res 2008;58:88-111. Go to original source...
    8. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-1602. Go to original source...
    9. Salio M, Chimenti S, De Angelis N, et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2008;117:1055-1064. Go to original source...
    10. Doukas J, Wrasidlo W, Noronha G, et al. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc Natl Acad Sci U S A 2006;103:19866-19871. Go to original source...
    11. Hilfiker-Kleiner D, Shukla P, Klein G, et al. Continuous glyco­ protein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation 2010;122:145-155. Go to original source...
    12. Weber KT, Sun Y, Campbell SE. Structural remodelling of the heart by fibrous tissue: role of circulating hormones and locally produced peptides. Eur Heart J 1995;16(Suppl N):12-18. Go to original source...
    13. van den Borne SW, Diez J, Blankeseijn WM, et al. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol 2010;7:30-37. Go to original source...
    14. Janicki JS, Brover GL. The role of myocardial fibrillar collagen in ventricular remodeling and function. J Cardiac Fail 2002;8(Suppl 6):S319-S325. Go to original source...
    15. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000;102:1388-1393. Go to original source...
    16. Diez J, Querejeta R, López B, et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002;105:2512-2517. Go to original source...
    17. López B, Querejeta R, González A, et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004;43:2028-2035. Go to original source...
    18. Zannad F, Radauceanu A. Effect of MR blockade on collagen form­ ation and cardiovascular disease with a specific emphasis on heart failure. Heart Fail Rev 2005;10:71-78. Go to original source...
    19. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myo­ cardial remodeling. Pharmacol Ther 2009;123:255-278. Go to original source...
    20. Hermida N, López B, Gonzálz A, et al. A synthetic peptide from transforming growth factor-ß type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovasc Res 2009;81:601-609. Go to original source...
    21. Trackman PC. Diverse biological functions of extracellular collagen processing enzymes. J Cell Biochem 2005;96:927-937. Go to original source...
    22. Bauersachs J. Regulation of myocardial fibrosis by micro RNAs. J Cardiovasc Pharmacol 2010;56:454-459. Go to original source...
    23. Thum T, Gross C, Fiedler J et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008;456:980-984. Go to original source...
    24. Berry MF, Engler AJ, Woo YJ, et al. Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. Am j Physiol Heart Circ Physiol 2006;290:H2196-H2203. Go to original source...
    25. Xu X, Xu Z, Xu Y, Cui G. Effects of mesenchymal stem cell transplantation on extracellular matrix after myocardial infarction in rats. Coron Artery Dis 2005;16:245-255. Go to original source...
    26. Gajarsa JJ, Kloner RA. Left ventricular remodeling in the post­ infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev 2011;16:13-21. Go to original source...
    27. López B, González A, Querejeta R, et al. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol 2006;48:89-96. Go to original source...
    28. Garcia RA, Go KV, Villarreal FJ. Effects of timed administration of doxycycline or methylprednisolone on post-myocardial infarction inflammation and left ventricular remodeling in the rat heart. Mol Cell Biochem 2007;300:159-169. Go to original source...
    29. Timmers L, Sluijter JP, Verlaan CW, et al. Cyclooxygenase-2 inhibit­ ion increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation 2007;115:326-332. Go to original source...
    30. Hudson MP, Armstrong PW, Ruzyllo W, et al. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J. Am Coll Cardiol 2006;48:15-20. Go to original source...
    31. Dormán G, Cseh S, Hajdú I, et al. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs 2010;70:949-964. Go to original source...
    32. Whelan RS, Kaplinskiy V, Kitsis RN. Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Phyiol 2010;72:19-44. Go to original source...
    33. Dorn GW Jr. Apoptotic and non-apoptotic programmed cardio­ myocyte death in ventricular remodelling. Cardiovasc Res 2009;81:465-473. Go to original source...
    34. Bae S, Siu PM, Choudhury S, et al. Delayed activation of caspaseindependent apoptosis during heart failure in transgenic mice overexpressing caspase inhibitor CrmA. Am J Physiol Heart Circ Physiol 2010;299;H1374-H1381. Go to original source...
    35. Bhuiyan MS, Fukunaga K. Inbihition of HtrA2/Omi ameliorates heart dysfunction following ischemia/reperfusion injury in rat heart in vivo. Eur J Pharmacol 2007;557:168-177. Go to original source...
    36. Ren X, Wu J, Wang X, et al. Micro RNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heatshock protein 20. Circulation 2009;119:2357-2366. Go to original source...
    37. Xu M, Uemura R, Dai Y, et al. In vitro and in vivo effects of bone marrow stem cells on cardiac structure and function. J Mol Cell Cardiol 2007;42:441-448. Go to original source...
    38. Singla DK, Lyons GE, Kamp TJ. transplanted embryonic stem cells following mouse myocardial infarction inhibit apoptosis and cardiac remodeling. Am J Physiol Heart Circ Physiol 2007;293:H1308-H1313. Go to original source...
    39. Kung G, Konstantinidis K, Kitsis RN. Programmed necrosis, not apoptosis, in the heart. Circ Res 2011;108:1017-1036. Go to original source...
    40. Boengler K, Hilfiker-Kleiner D, Heusch G, et al. Inhibition of perme­ability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. Basic Res Cardiol 2010;105:771-785. Go to original source...
    41. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359:473-481. Go to original source...
    42. Matsui Y, Takagi H, Qu X, et al. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and beclin 1 in mediating autophagy. Circ Res 2007;100:914-922. Go to original source...
    43. Camara AK, Bienengraeber M, Stowe DF. Mitochondrial approach­ es to protect against cardiac ischemia and reperfusion injury. Front Physiol 2011;2:1-34. Go to original source...
    44. Niebauer J, Pflaum CD, Clark AL, et al. Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. J Am Coll Cardiol 1998;32:393-397. Go to original source...
    45. Anker SD, Volterrani M, Pflaum CD, et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol 2001;38:443-452. Go to original source...
    46. Sarkley JP, Chu M, McShane M, et al. Nogo-A knockdown inhibits hypoxia/reoxygenation-induced activation of mitochondrialdependent apoptosis in cardiomyocytes. J Mol Cell Cardiol 2011;50:1044-1055. Go to original source...
    47. Yoon YS, Uchida S, Masuo E, et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 2005;111:2073-2085. Go to original source...
    48. Xue W, Cai L, Tan Y, et al. Cardiac-specific overexpression of HIF1α prevents deterioration of glycolitic pathway and cardiac remodeling in streptozotocin-induced diabetic mice. Am J Pathol 2010;177:97-105. Go to original source...
    49. Cataliotti A, Tonne JM, Bellavia D, et al. Long-term cardiac pro-Btype natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation 2011;123:1297-1305. Go to original source...
    50. Cardinale JP, Sriramula S, Pariaut R, et al. HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension 2010;56:437-444. Go to original source...
    51. Lionetti V, Bianchi G, Recchia FA, Ventura C. Control of autocrine and paracrine myocardial signals: an emerging therapeutic strategy in heart failure. Heart Fail Rev 2010;15:531-542. Go to original source...
    52. Liu Q, Anderson C, Broyde PA, et al. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 2010;9:76-89. Go to original source...
    53. Liu Q, Adams LO, Broyde A, et al. The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl SALT-sensitive rats. Cardiovasc Diabetol 2010;9:32-41. Go to original source...
    54. D´Ascia' C, Cittadini A, Monti MG, et al. Effects of biventricular pacing on interstitial remodelling, tumor necrosis factor-alpha expression, and apoptotic death in failing human myocardium. Eur Heart J 2006;27:201-206. Go to original source...

    Return to the content